Endocrinology, Vol 135, 589-594, Copyright © 1994 by Endocrine Society

ARTICLES

Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action

C Montrose-Rafizadeh, JM Egan and J Roth
National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224.

Glucagon-like peptide-1-(7-36) amide (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are known incretin hormones, released from enteroendocrine cells in response to food, that enhance insulin secretion, but only in the presence of elevated blood glucose. We used a rat insulinoma cell line, RIN 1046-38, to study the mechanisms underlying the interaction of incretins and glucose. We measured insulin secretion using RIA and the reverse hemolytic plaque assay. GLP- 1 stimulates insulin secretion, with a half-maximal concentration of 34 pM. GLP-1 is approximately 2 orders of magnitude more potent than GIP. GLP-1 and GIP have additive effects at submaximal concentrations, but probably not at maximal concentrations, suggesting a common signal transduction pathway. The glucose requirement for GLP-1 action can be replaced by cell membrane depolarization (20 mM KCl in the extracellular medium), suggesting that a rise of intracellular Ca2+ may be an early step required for GLP-1 action. GLP-1 stimulates insulin secretion by significantly increasing the maximum rate of insulin secretion from 10.3 +/- 2.25 to 25.2 +/- 2.94 ng insulin/mg protein.h. GLP-1 acts by recruiting 1.5-fold more cells to secrete insulin as well as enhancing insulin secretion by individual cells. Combinations of stimuli, such as glucose, cell membrane depolarization, and GLP-1, can recruit 90% of RIN 1046-38 cells to secrete insulin.

This article has been cited by other articles:

				W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF]

				L. Shu, N. S. Sauter, F. T. Schulthess, A. V. Matveyenko, J. Oberholzer, and K. Maedler Transcription Factor 7-Like 2 Regulates {beta}-Cell Survival and Function in Human Pancreatic Islets Diabetes, March 1, 2008; 57(3): 645 - 653. [Abstract] [Full Text] [PDF]

				M. E. Doyle and J. M. Egan Pharmacological Agents That Directly Modulate Insulin Secretion Pharmacol. Rev., March 1, 2003; 55(1): 105 - 131. [Abstract] [Full Text] [PDF]

				T. Perry, D. K. Lahiri, D. Chen, J. Zhou, K. T. Y. Shaw, J. M. Egan, and N. H. Greig A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 958 - 966. [Abstract] [Full Text] [PDF]

				M. E. Doyle, N. H. Greig, H. W. Holloway, J. A. Betkey, M. Bernier, and J. M. Egan Insertion of an N-Terminal 6-Aminohexanoic Acid after the 7 Amino Acid Position of Glucagon-Like Peptide-1 Produces a Long-Acting Hypoglycemic Agent Endocrinology, October 1, 2001; 142(10): 4462 - 4468. [Abstract] [Full Text] [PDF]

				H. Yang, J. M. Egan, B. D. Rodgers, M. Bernier, and C. Montrose-Rafizadeh Differential Expression of a Novel Seven Transmembrane Domain Protein in Epididymal Fat from Aged and Diabetic Mice Endocrinology, June 1, 1999; 140(6): 2859 - 2867. [Abstract] [Full Text]

				C. Montrose-Rafizadeh, P. Avdonin, M. J. Garant, B. D. Rodgers, S. Kole, H. Yang, M. A. Levine, W. Schwindinger, and M. Bernier Pancreatic Glucagon-Like Peptide-1 Receptor Couples to Multiple G Proteins and Activates Mitogen-Activated Protein Kinase Pathways in Chinese Hamster Ovary Cells Endocrinology, March 1, 1999; 140(3): 1132 - 1140. [Abstract] [Full Text]

				H. Yang, J. M. Egan, Y. Wang, C. D. Moyes, J. Roth, M. H. Montrose, and C. Montrose-Rafizadeh GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor Am J Physiol Cell Physiol, September 1, 1998; 275(3): C675 - C683. [Abstract] [Full Text] [PDF]